With a goal of eradicating hepatitis C, NHS England has teamed up Gilead Sciences Inc., Merck & Co. and AbbVie Inc.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
The new generation of hep C drugs has completely changed the conversation about launches.
Merck award may be in jeopardy after reports a former Merck scientist lied to a jury about claims he was responsible for developig hepatitis drugs Gilead was accused of infringing upon.
U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors. The list price for Zepatier will be $54,600 for a 12-week regimen, which Merck said it expects “to be […]
Massachusetts’ attorney general is studying whether the prices of Gilead Sciences Inc’s blockbuster treatments for hepatitis C violate state law, according to a letter the prosecutor sent to the California drugmaker. The letter from Attorney General Maura Healey to Gilead Chief Executive Officer John Martin, dated January 22, asked the biotechnology company to reconsider its […]
With the 2015 record-breaking biopharma merger-and-acquisition period about to come to an end, analysts are tuning their crystal balls to 2016. So far this year—not quite done yet—there has been $667.5 billion in healthcare mergers and acquisitions, according to Dealogic. Next year is likely to continue a trend that started, or at least accelerated, last […]
U.S. state Medicaid programs spent $1.3 billion before rebates in 2014 on Gilead Sciences’ new hepatitis C drugs to treat fewer than 2.4 percent of enrollees with the liver disease, according to a U.S. Senate investigation into pricing of the blockbuster medicines. In the latest salvo against high U.S. prices for important medicines, the 18-month […]